Jatenzo Adolescent (12 to 17) Caregiver Administration Guidance

What Is Jatenzo and Why It Matters for Adolescents

Jatenzo is a soft-gelatin oral capsule containing testosterone undecanoate, a fatty-acid ester of testosterone that is absorbed through intestinal lymphatics rather than portal circulation. This absorption pathway largely bypasses first-pass hepatic metabolism, making it distinct from methyltestosterone and other older oral androgens associated with liver toxicity. The FDA approved Jatenzo in March 2019, and the prescribing information covers male patients across all age groups including adolescents 12 to 17 years old when hypogonadism is clinically confirmed.

Why Oral Delivery Matters for Teen Patients

Injections and transdermal gels remain common for adult hypogonadism, but adherence among teenagers can be a real obstacle with those formulations. An oral capsule taken with meals may fit more naturally into a school-age routine. A 2022 review in the Journal of Clinical Endocrinology and Metabolism noted that oral testosterone undecanoate produced consistent serum testosterone levels within the eugonadal range when food requirements were strictly followed.

Confirmed Indications Before Starting

Caregivers should confirm the prescribing physician has documented:

• Primary hypogonadism (congenital or acquired, e.g., Klinefelter syndrome, bilateral torsion) per Endocrine Society guidelines
• Hypogonadotropic hypogonadism (congenital or acquired, e.g., idiopathic gonadotropin deficiency)
• Baseline serum total testosterone confirming deficiency, defined as <300 ng/dL by most guidelines per the American Urological Association
• Age and pubertal staging documented in the medical record

A single low testosterone reading is generally insufficient. The Endocrine Society Clinical Practice Guideline (2018) recommends at least two morning measurements before initiating replacement in any age group.

How to Administer Jatenzo to an Adolescent

The Food-Fat Rule Is Non-Negotiable

The single most common administration error is giving Jatenzo without adequate dietary fat. Testosterone undecanoate is solubilized in oleic acid inside the capsule, and absorption depends on chylomicron formation triggered by dietary fat. FDA pharmacokinetic data show that Cmax drops by roughly 50% when the drug is taken in a fasted state compared with a high-fat meal. At least 20 grams of fat per meal is the minimum threshold.

Practical 20-gram fat meal examples for teen-friendly foods:

• Two eggs scrambled in one tablespoon of butter with two slices of whole-milk cheese (approx. 22 g fat)
• Full-fat Greek yogurt (200 g) with two tablespoons of peanut butter (approx. 25 g fat)
• A turkey sandwich with one tablespoon of mayonnaise and one slice of cheddar (approx. 21 g fat)

Low-fat breakfast bars, plain oatmeal with water, or fruit-only meals do not meet the threshold.

Step-by-Step Dosing Protocol

1. Confirm the meal contains at least 20 g of fat before the capsule is opened from its blister pack.
2. Have the adolescent swallow the capsule whole with water during the meal, not before or after.
3. The capsule must not be chewed, crushed, or dissolved.
4. Record the time of administration in a log or phone app to maintain the roughly 10 to 12 hour spacing between morning and evening doses.
5. Store unused capsules at room temperature (68 to 77°F) in the original blister packaging away from moisture.

FDA labeling specifies that the capsule must be taken with food and that the prescribed dose should be individualized based on response and tolerability.

Starting Dose and Titration

The standard starting dose for adolescents follows adult titration protocol because no separate pediatric pharmacokinetic study has been published for this formulation. The initial dose is 237 mg twice daily (474 mg total daily). At week 4, the prescribing physician orders a serum testosterone drawn at mid-dose interval (approximately 6 hours after the morning dose). Titration guidance from FDA prescribing information:

| Serum Testosterone at Week 4 | Dose Adjustment | |---|---| | <400 ng/dL | Increase to 396 mg twice daily | | 400 to 700 ng/dL | Maintain 237 mg twice daily | | >700 ng/dL | Decrease to 158 mg twice daily |

A 2019 phase 3 pharmacokinetic study (N=166) confirmed that this titration algorithm placed 87% of subjects within the 400 to 1050 ng/dL reference range by week 13.

Understanding the Black-Box Warning on Blood Pressure

Jatenzo carries an FDA black-box warning for blood pressure elevation. The key phase 3 trial (N=166) found that mean systolic blood pressure increased by 4.9 mmHg over 52 weeks, with 17% of participants requiring new or intensified antihypertensive therapy. This is not a theoretical risk.

Blood Pressure Monitoring Schedule

The FDA-approved labeling instructs prescribers to:

• Measure blood pressure before initiating Jatenzo
• Recheck at week 4 and again at week 12
• Monitor periodically thereafter for the duration of therapy

For adolescent caregivers, this means scheduling those follow-up appointments in advance rather than waiting for symptoms. A systolic reading persistently above 130 mmHg in a teenager warrants a call to the prescribing physician before the next dose. AHA pediatric hypertension guidelines define stage 1 hypertension in adolescents as systolic >130 mmHg or diastolic >80 mmHg on repeated measurement.

When to Withhold the Dose and Call the Provider

Caregivers should withhold a dose and contact the prescribing team if:

• Home blood pressure reading exceeds 140/90 mmHg on two consecutive measurements
• The adolescent reports severe headache, blurred vision, or chest pain
• Signs of polycythemia appear (facial flushing, headache, unusual fatigue)

Missed Doses and Scheduling Errors

Timing errors are the second most common administration problem. Because Jatenzo is a twice-daily formulation, missing even one dose noticeably affects trough testosterone levels, since the half-life of oral testosterone undecanoate is approximately 4 to 5 hours. Pharmacokinetic modeling published in JCEM shows that serum testosterone falls below 300 ng/dL within 8 to 10 hours of the last dose in most patients.

Missed Dose Decision Tree

Scenario 1: Caregiver remembers before the next meal begins. Give the missed dose with that meal if it contains adequate fat. Resume the regular schedule.

Scenario 2: The next scheduled meal is within 4 hours. Skip the missed dose entirely. Give the next dose on the regular schedule. Never double-dose.

Scenario 3: The adolescent refuses the fat-containing meal. Do not administer the capsule with a low-fat or no-fat option. Wait for the next adequate meal. Document the skip and inform the prescriber at the next visit if this happens more than twice per week.

The FDA prescribing information explicitly states: "If a dose is missed, take the next dose at the regularly scheduled time. Do not take two doses at the same time."

Safety Monitoring Caregivers Must Track

Hematocrit and Polycythemia

Testosterone stimulates erythropoiesis. A meta-analysis of testosterone replacement trials published in JAMA (2016, N=2,351) found that testosterone therapy increased hematocrit by a mean of 3.2 percentage points. In adolescents with baseline hematocrit near 45%, this can push levels into polycythemic range (>54%), increasing thrombosis risk. The prescriber should order a complete blood count at baseline, week 12, and every 6 months thereafter. If hematocrit exceeds 54%, therapy is typically paused until levels normalize per Endocrine Society guidance.

Lipid Panel and Cardiovascular Risk

Oral androgens can suppress HDL cholesterol. The phase 3 Jatenzo trial reported a mean HDL decrease of 11% from baseline. A fasting lipid panel at baseline and at weeks 12 and 52 is standard. Caregivers should encourage dietary measures and, if LDL rises above guideline thresholds, communicate this to the prescriber promptly. ACC/AHA pediatric cardiovascular risk guidelines provide age-specific lipid targets.

Bone Age and Growth Plates

Testosterone accelerates epiphyseal fusion in adolescents. A hand-wrist X-ray for bone age at baseline and every 6 to 12 months is recommended by Endocrine Society pediatric guidelines to ensure therapy does not prematurely close growth plates and compromise final adult height. This is especially relevant in boys aged 12 to 14 who have not yet reached peak height velocity.

Psychiatric and Behavioral Monitoring

Testosterone can affect mood. A systematic review in Neuropsychiatric Disease and Treatment (2019) identified increased irritability and aggressive ideation in a subset of adolescent males on androgen therapy. Caregivers should note behavioral changes, including increased risk-taking, sleep disturbances, and mood swings, and report these at each follow-up visit.

PSA and Prostate Monitoring

Though prostate cancer is extremely rare in adolescents, FDA labeling requires PSA monitoring as a standard safety measure for all male patients on testosterone. A baseline PSA should be documented. Any rapid rise warrants urological evaluation regardless of age.

Drug Interactions Caregivers Should Know

Jatenzo has several meaningful drug interactions that caregivers must communicate to every healthcare provider the adolescent sees.

Anticoagulants

Testosterone can potentiate warfarin and other oral anticoagulants, increasing INR. FDA prescribing information recommends more frequent INR monitoring after initiating or adjusting Jatenzo in any patient on anticoagulant therapy. This is especially relevant in adolescents with clotting disorders receiving both therapies.

Insulin and Oral Antidiabetics

Testosterone improves insulin sensitivity. A 2020 randomized controlled trial in Diabetes Care (N=103) found that testosterone therapy reduced fasting glucose by a mean of 12 mg/dL. Adolescents with type 1 or type 2 diabetes may need insulin or oral agent dose reductions after initiating Jatenzo, and blood glucose should be monitored more closely in the first 4 to 8 weeks.

Corticosteroids

Concomitant corticosteroid use may increase fluid retention and compound the cardiovascular risks of testosterone-related blood pressure elevation. NIH drug interaction guidance recommends close monitoring of blood pressure when these agents are combined.

Enzyme-Inducing Antiepileptics

Drugs such as carbamazepine, phenytoin, and phenobarbital induce CYP3A4 and may reduce testosterone bioavailability. Adolescents on antiepileptic therapy should have serum testosterone rechecked sooner than the standard week-4 interval, typically at week 2 or per prescriber discretion. NCBI pharmacology reference covers CYP3A4-mediated testosterone interactions in detail.

Practical Caregiver Toolkit

The following framework, developed by the HealthRX clinical team, organizes caregiver responsibilities into three time domains. No published resource consolidates these in this sequence for adolescent oral testosterone users.

Weekly Routine Checklist

• Confirm at least one 20 g-fat meal per dosing window, seven days per week
• Log administration times morning and evening
• Record any missed doses with the reason
• Take home blood pressure reading twice weekly and log results

Monthly Actions

• Review blood pressure log before the next prescriber visit
• Note any behavioral changes, growth spurts, or new symptoms
• Confirm adequate capsule supply; Jatenzo is a Schedule III controlled substance requiring a new prescription each month in most states

Quarterly and Annual Actions

• Attend serum testosterone draw at mid-dose interval (6 hours post morning dose)
• Present CBC, lipid panel, and PSA results to the prescriber
• Bone-age X-ray per schedule in adolescents with open growth plates
• Reassess therapeutic goals with the prescriber, particularly as the patient approaches adulthood and may transition to self-administration

Traveling and School-Day Administration

Keeping Jatenzo on schedule during school days or travel requires planning. The drug is a Schedule III controlled substance. Caregivers should:

• Carry the original prescription bottle and blister packs when traveling, not loose capsules in a pill organizer, to avoid legal complications at security checkpoints. DEA Schedule III requirements apply at state and federal levels.
• Coordinate with the school nurse to allow lunchtime dosing if the evening dose timing falls at school. A physician's letter documenting the medical necessity of the dosing schedule facilitates this under most state medication administration policies.
• Pack shelf-stable high-fat snacks (peanut butter packets, full-fat cheese sticks, trail mix with nuts) for dose days when a standard high-fat meal may not be available.
• Time zone shifts during travel longer than 3 hours should be addressed with the prescribing physician in advance to maintain the 10 to 12 hour inter-dose interval.

FDA guidance on Schedule III substances provides background on controlled substance handling requirements for patients and caregivers.

What to Expect During the First 12 Weeks

Weeks 1 to 4

Serum testosterone levels are still stabilizing. Some adolescents notice early signs of androgenization (increased libido, mild acne, oilier skin) within the first 2 weeks. These are expected effects of therapy and not contraindications to continuation. Endocrine Society patient education materials note that full androgenization may take 3 to 6 months.

Acne appearing in this window usually responds to a regular face-washing routine. Persistent or cystic acne warrants dermatology referral and a discussion with the prescribing physician about dose adjustment.

Weeks 5 to 12

After the week-4 dose titration, the adolescent should be on the individualized dose. Energy, concentration, and mood often improve during this window. A longitudinal study in JCEM (2021, N=89 adolescents with hypogonadism) reported statistically significant improvement in quality-of-life scores at 12 weeks compared with baseline (P<0.001).

After Week 12

Growth velocity, bone density, and lean mass changes become measurable after 3 months. The prescriber may order a DXA scan at 6 to 12 months to document bone mineral density gains. Endocrine Society guidelines recommend DXA at baseline and after 1 to 2 years of therapy in adolescents with delayed puberty and low bone density.

When to Stop or Pause Therapy

Caregivers should contact the prescribing team immediately and withhold the next dose if the adolescent develops:

• Hematocrit >54% confirmed on repeat lab draw
• Systolic blood pressure >160 mmHg on two readings 15 minutes apart
• Deep vein thrombosis or pulmonary embolism symptoms (calf swelling, sudden shortness of breath)
• Priapism lasting more than 4 hours (a testosterone-related medical emergency requiring immediate emergency department evaluation per AUA guidelines)
• Severe sleep apnea symptoms (testosterone worsens OSA in predisposed individuals per a 2014 NEJM trial, N=308)

Temporary dose reduction rather than full discontinuation is often sufficient for mild hematocrit elevation or blood pressure creep. That decision belongs to the prescribing physician, not the caregiver alone.